Stockscreener 앱 받기
14.85
0.13%
-0.02
전일 마감가:
$14.87
열려 있는:
$14.78
하루 거래량:
776.68K
Relative Volume:
0.57
시가총액:
$1.96B
수익:
$260.11M
순이익/손실:
$60.64M
주가수익비율:
34.53
EPS:
0.43
순현금흐름:
$92.29M
1주 성능:
-1.98%
1개월 성능:
-6.31%
6개월 성능:
+67.80%
1년 성능:
+91.86%
1일 변동 폭
$14.78
$15.08
1주일 범위
$14.74
$15.31
52주 변동 폭
$6.55
$16.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
명칭
Aurinia Pharmaceuticals Inc
전화
250-744-2487
주소
#140, 14315 - 118 AVENUE, EDMONTON, BC
AUPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
14.85 | 1.96B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-11-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-05-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-05-05 | 개시 | Cowen | Outperform |
| 2020-01-10 | 개시 | Jefferies | Buy |
| 2019-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-16 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-10-30 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-22 | 재확인 | FBR & Co. | Outperform |
| 2016-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2016-06-30 | 개시 | H.C. Wainwright | Buy |
| 2015-05-08 | 개시 | MLV & Co | Buy |
모두보기
Aurinia Pharmaceuticals Inc 주식(AUPH)의 최신 뉴스
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - sharewise.com
Trading the Move, Not the Narrative: (AUPH) Edition - Stock Traders Daily
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: 9.08% Potential Upside Amid Promising Biotech Innovations - DirectorsTalk Interviews
With 54% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance
How Aurinia Pharmaceuticals Inc. stock responds to policy changesWeekly Earnings Recap & Growth Focused Entry Point Reports - Улправда
Aurinia Pharmaceuticals (NASDAQ:AUPH) Share Price Passes Above 50-Day Moving AverageHere's Why - MarketBeat
How strong is Aurinia Pharmaceuticals Inc. stock balance sheetJuly 2025 Patterns & Growth Oriented Trade Recommendations - ulpravda.ru
Is Aurinia Pharmaceuticals Inc. stock a top pick in earnings seasonTrade Analysis Report & Precise Swing Trade Entry Alerts - ulpravda.ru
Earnings Report: Why Aurinia Pharmaceuticals Inc. (IKAP) stock stays resilientProfit Target & Weekly Top Gainers Trade List - Улправда
Is Aurinia Pharmaceuticals Inc. (IKAP) stock resilient in recession scenarios2025 Technical Patterns & Low Risk High Reward Ideas - Улправда
Why Aurinia Pharmaceuticals Inc. (IKAP) stock is listed among top recommendationsPortfolio Update Summary & Stock Timing and Entry Methods - Улправда
Why retail investors favor Aurinia Pharmaceuticals Inc. stockSupport Zone Identification & Free High Yield Growth Strategies - Улправда
Aruinia discloses FDA information request on Lupkynis amid top regulator’s exit - MSN
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Riding the Biotech Wave with 8.93% Potential Upside - DirectorsTalk Interviews
RBC Capital Downgrades Aurinia Pharmaceuticals (AUPH) - MSN
Aug Sectors: Why retail investors favor Aurinia Pharmaceuticals Inc. stockTrade Entry Report & Smart Swing Trading Alerts - moha.gov.vn
Aurinia Pharmaceuticals IncCommon Shares (NQ: AUPH - FinancialContent
(AUPH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Down 3.6%Here's Why - MarketBeat
Aurinia Pharmaceuticals (AUPH) Price Target Increased by 34.15% to 16.03 - MSN
Aurinia downgraded at RBC on risk-reward setup - MSN
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Is a Favorite Amongst Institutional Investors Who Own 54% - 富途牛牛
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: A Biotech Contender with a 4.89% Upside - DirectorsTalk Interviews
Spoke.comAurinia Pharmaceuticals IncCommon Shares (Nasdaq:AUPH) Stock Quote - FinancialContent
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? - AOL.com
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year? - sharewise.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) rises 3.1% this week, taking three-year gains to 292% - simplywall.st
Understanding the Setup: (AUPH) and Scalable Risk - Stock Traders Daily
How Aurinia Pharmaceuticals Inc. (IKAP) stock trades pre earningsDebt-to-Equity Ratio Analysis & Watch and Learn From Live Trades - bollywoodhelpline.com
Aurinia Pharmaceuticals stock hits 52-week high at 16.49 USD By Investing.com - Investing.com Australia
Aurinia Pharmaceuticals (NASDAQ:AUPH) Hits New 12-Month HighHere's Why - MarketBeat
Aurinia Pharmaceuticals stock hits 52-week high at 16.49 USD - Investing.com
Why Aurinia Pharmaceuticals Inc. (IKAP) stock gets analyst attentionWeekly Market Outlook & Stock Timing and Entry Methods - Улправда
Chart Watch: Will Aurinia Pharmaceuticals Inc. stock pay special dividendsWall Street Watch & Free Risk Controlled Daily Trade Plans - Улправда
Will Aurinia Pharmaceuticals Inc. stock outperform international peersWeekly Stock Recap & Weekly High Return Stock Opportunities - Bölüm Sonu Canavarı
Is Aurinia Pharmaceuticals Inc. stock supported by innovation pipelineJuly 2025 Sector Moves & Community Verified Watchlist Alerts - DonanımHaber
Is Aurinia Pharmaceuticals Inc. (IKAP) stock undervalued after correction2025 Buyback Activity & Smart Swing Trading Techniques - DonanımHaber
Will Aurinia Pharmaceuticals Inc. stock benefit from automationPortfolio Value Report & Proven Capital Preservation Methods - DonanımHaber
Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Inc $AUPH Shares Purchased by Squarepoint Ops LLC - MarketBeat
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors - Yahoo Finance
Marex Group plc Buys Shares of 135,000 Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Assessing Aurinia Pharmaceuticals After Its 80% 2025 Surge and Lupus Nephritis Momentum - Yahoo Finance
How (AUPH) Movements Inform Risk Allocation Models - Stock Traders Daily
Armistice Capital LLC Sells 3,370,400 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals Inc $AUPH Shares Purchased by Jump Financial LLC - MarketBeat
Aurinia Pharmaceuticals Inc (AUPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aurinia Pharmaceuticals Inc 주식 (AUPH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
4.73%
0.92%
자본화:
|
볼륨(24시간):